Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites

Validation of an analytical LC-MS/MS method in human plasma for the pharmacokinetic study of atomoxetine

(2013) C. I. Choi et al.   JOURNAL OF ANALYTICAL CHEMISTRY

Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study

(2011) Chang-Ik Choi et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect ofCYP2D6*10/*10Genotype in Healthy Japanese Men

(2011) A. Matsui et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Recognition of Impaired Atomoxetine Metabolism Because of Low CYP2D6 Activity

(2010) Maureen A. ter Laak et al.   PEDIATRIC NEUROLOGY

Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents

(2009) Daniel Scherer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Discovery of Novel Functional Variants and Extensive Evaluation of CYP2D6 Genetic Polymorphisms in Koreans

(2009) S.-J. Lee et al.   DRUG METABOLISM AND DISPOSITION

Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers

(2009) Q. Li et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese

(2009) Q Zhou et al.   PHARMACOGENOMICS JOURNAL

Influence ofCYP2D6*10on the pharmacokinetics of metoprolol in healthy Korean volunteers

(2008) S. K. Jin et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS